In addition, HDAC inhibitors or HAT activators have been employed in clinics to treat the neurological symptoms of neurodegenerative diseases and psychiatric disorders, as well as autism, memory loss, and cognitive function, although not always successfully (Christopher et al., 2017; Delgado-Morales et al., 2017; Selvi et al., 2010; Ganai et al., 2016). This evidence concerns the gene TMPRSS11D and autism.